SCENESSE® applied under five-year Veterans Affairs contract
CLINUVEL has been awarded a five-year contract by the U.S. Department of...
Read More
CLINUVEL secures IP for melanocortins to treat central nervous system disorders
CLINUVEL has secured a family of patents and patent applications relating to...
Read More
Notification regarding unquoted securities
CLINUVEL today released a notification regarding unquoted securities.
Read More
Two grounds of Appeal upheld by NICE Panel
In an announcement released today, CLINUVEL provided an updated on the outcome...
Read More
News Kommuniqué III
Melbourne, Australia, 26 June 2023 ASX: CUV XETRA-DAX: UR9 Level 1 ADR:...
Read More
Notification of cessation of securities
CLINUVEL today released a notification regarding cessation of securities.
Read More
Twilight Event - Briefing
CLINUVEL presented during a Twilight Briefing, after the close of market yesterday....
Read More
Change of Director’s Interest Notice
CLINUVEL today released a notification regarding a change of Director’s interest.
Read More
News Communiqué III
CLINUVEL’s News Communiqué III reviews the Company’s trajectory, and underlying reasons to...
Read More
CLINUVEL Bulletin Edition 01
The first in a new series providing updates on CLINUVEL's Brand Architecture,...
Read More
CLINUVEL escalates PRÉNUMBRA® to moderate/severe stroke patients
CLINUVEL announced the escalation of PRÉNUMBRA® Instant to moderate-to-severe and severe stroke...
Read More
Expansion of CLINUVEL’s global porphyria programs
CLINUVEL today released an update on the use its drug SCENESSE® (afamelanotide...
Read More
News Kommuniqué II
Melbourne, Australia, 12 January 2023 ASX: CUV XETRA-DAX: UR9 Level 1 ADR:...
Read More
News Communiqué I - Ms Cristina Ramos
Introducing CLINUVEL’s next Intriguing Personality (CUVIP), Ms Cristina Ramos.
Read More